Group 1 - Biogen has reinvigorated its Immunology and Inflammation (I&I) efforts, indicating a strategic shift beyond its historical focus on neuroscience [1] - The company's expertise in neuro-immunology, particularly in the central nervous system (CNS), underpins its strategy in I&I and kidney areas [1] - Biogen has been involved in lupus research for over a decade, highlighting its long-term commitment to immunological pathways [2] Group 2 - The development of drugs targeting immunological pathways is aimed at supporting a diverse product portfolio [2]